{"id":"alizapride","rwe":[],"tags":[{"label":"alizapride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(2) dopamine receptor","category":"target"},{"label":"DRD2","category":"gene"},{"label":"ADRA2C","category":"gene"},{"label":"A03FA05","category":"atc"},{"label":"Active","category":"status"},{"label":"Nausea and vomiting","category":"indication"},{"label":"Postoperative nausea and vomiting","category":"indication"},{"label":"Antiemetics","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":111.373,"date":"","count":40,"signal":"Febrile bone marrow aplasia","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=111)"},{"llr":93.48,"date":"","count":55,"signal":"Encephalopathy","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=93)"},{"llr":67.757,"date":"","count":33,"signal":"Polyneuropathy","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=68)"},{"llr":64.078,"date":"","count":83,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 83 times (LLR=64)"},{"llr":63.433,"date":"","count":75,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 75 times (LLR=63)"},{"llr":58.95,"date":"","count":57,"signal":"Hypokalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=59)"},{"llr":56.965,"date":"","count":16,"signal":"Hypofibrinogenaemia","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=57)"},{"llr":55.575,"date":"","count":9,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=56)"},{"llr":55.223,"date":"","count":81,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 81 times (LLR=55)"},{"llr":53.061,"date":"","count":28,"signal":"Hyperbilirubinaemia","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=53)"},{"llr":49.682,"date":"","count":74,"signal":"General physical health deterioration","source":"DrugCentral FAERS","actionTaken":"Reported 74 times (LLR=50)"},{"llr":48.147,"date":"","count":16,"signal":"Persecutory delusion","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=48)"},{"llr":42.4,"date":"","count":79,"signal":"Decreased appetite","source":"DrugCentral FAERS","actionTaken":"Reported 79 times (LLR=42)"},{"llr":40.997,"date":"","count":23,"signal":"Bronchospasm","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=41)"},{"llr":36.669,"date":"","count":15,"signal":"Aplasia","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=37)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALIZAPRIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:25:09.569333+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:25:24.593668+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:25:15.108602+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALIZAPRIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:25:15.557725+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1896987/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:25:16.275391+00:00"}},"allNames":["alizapride","alizapride hydrochloride","alizapride HCl"],"offLabel":[],"synonyms":["alizapride","alizapride hydrochloride","alizapride HCl"],"timeline":[{"date":"1981-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Alizapride is a small molecule dopamine D2 receptor antagonist. It has been studied in clinical trials for conditions such as chemotherapy-induced nausea and vomiting, nausea, and vomiting, including in patients with early breast cancer.","ecosystem":[{"indication":"Nausea and vomiting","otherDrugs":[{"name":"chlorpromazine","slug":"chlorpromazine","company":"Glaxosmithkline"},{"name":"dimenhydrinate","slug":"dimenhydrinate","company":"Alra"},{"name":"perphenazine","slug":"perphenazine","company":""},{"name":"prochlorperazine","slug":"prochlorperazine","company":"Glaxosmithkline"}],"globalPrevalence":null},{"indication":"Postoperative nausea and vomiting","otherDrugs":[{"name":"amisulpride","slug":"amisulpride","company":"Acacia Pharma Ltd"},{"name":"benzquinamide","slug":"benzquinamide","company":""}],"globalPrevalence":null}],"mechanism":{"target":"D(2) dopamine receptor","targets":[{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"}],"modality":"Small Molecule","drugClass":"alizapride","explanation":"","oneSentence":"","technicalDetail":"Alizapride acts as a selective dopamine D(2) receptor antagonist, which inhibits the dopaminergic transmission in the chemoreceptor trigger zone, thereby reducing the emetic response."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/120","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALIZAPRIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALIZAPRIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:37:27.626595","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:25:24.593760+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"metoclopramide","drugSlug":"metoclopramide","fdaApproval":"1979-02-07","patentExpiry":"Nov 17, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cisapride","drugSlug":"cisapride","fdaApproval":"1993-07-29","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"alizapride","indications":{"approved":[{"name":"Nausea and vomiting","source":"DrugCentral","snomedId":16932000,"regulator":"FDA"},{"name":"Postoperative nausea and vomiting","source":"DrugCentral","snomedId":1488000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metoclopramide","brandName":"metoclopramide","genericName":"metoclopramide","approvalYear":"1979","relationship":"same-class"},{"drugId":"cisapride","brandName":"cisapride","genericName":"cisapride","approvalYear":"1993","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01298193","phase":"PHASE4","title":"Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2011-05","conditions":["Breast Cancer"],"enrollment":212,"completionDate":"2014-04"},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":["Nausea","Vomiting"],"enrollment":494,"completionDate":"2014-08-04"},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":["Chemotherapy-Induced Nausea and Vomiting (CINV)"],"enrollment":1015,"completionDate":"2014-11-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005228","UNII":"P55703ZRZY","CHEBI":"CHEBI:94316","INN_ID":"4823","RXNORM":"17311","UMLSCUI":"C0051162","chemblId":"CHEMBL1896987","ChEMBL_ID":"CHEMBL290194","KEGG_DRUG":"D07102","DRUGBANK_ID":"DB01425","PUBCHEM_CID":"135497066","SNOMEDCT_US":"724156007","IUPHAR_LIGAND_ID":"11141","SECONDARY_CAS_RN":"59338-87-3","MESH_SUPPLEMENTAL_RECORD_UI":"C033968"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.8 hours","clearance":"6.6 mL/min/kg","bioavailability":"84%","volumeOfDistribution":"1.6 L/kg"},"publicationCount":110,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A03FA05","allCodes":["A03FA05"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ALIZAPRIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:25:24.593760+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}